Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.
Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.
复制标题
唑吡坦、三唑仑和替马西泮：对正常志愿者的行为和受试者评价影响。
DOI：
10.1097/00004714-199604000-00007
复制
发表时间：
1996
影响因子：
2.9
通讯作者：
Griffiths,RR
中科院分区：
文献类型：
--
作者：
Rush,CR;Griffiths,RR
唑吡坦是一种咪唑吡啶类催眠药，在生物化学上不同于经典的苯二氮卓类激动剂，因为它可能对bz1受体亚型具有选择性，并且显示出不同的结合位点分布模式。本研究比较了唑吡坦、三唑安定和替马西泮对11名健康人的学习、回忆、表现、受试者评价和观察者评价的影响。在随机、双盲、交叉设计中，口服安慰剂、唑吡坦（5、10和20 mg/70 kg）、三唑仑（0.125、0.25和0.50 mg/70 kg）和替马西泮（15、30和60 mg/70 kg）。唑吡坦、三唑仑和替马西泮产生了与剂量和时间相关的学习、回忆和表现损伤，并增加了受试者和观察者对药物作用强度的评估。在三种化合物中，这些效应的绝对幅度在峰值效应时具有可比性。唑吡坦组（0.5 ~ 1.0 h）比三唑仑组（1.5 ~ 2.0 h）和替马西泮组（2 ~ 3 h）达到最大药效的时间要快。这些结果表明，尽管唑吡坦具有某种独特的苯二氮卓类受体结合特征，但其行为和受试者评价效果与苯二氮卓类催眠药物（即三唑仑和替马西泮）相似。[J] .中华精神病学杂志，1996,32(4):387 - 398。
Zolpidem is an imidazopyridine hypnotic that is biochemically distinct from classic benzodiazepine agonists in that it may be selective for the BZ 1 receptor subtype and shows a different pattern of distribution of binding sites. The present study compared the learning, recall, performance, subject-rated and observer-rated effects of zolpidem, triazolam, and temazepam in 11 healthy humans. Placebo, zolpidem (5, 10, and 20 mg/70 kg), triazolam (0.125, 0.25, and 0.50 mg/70 kg), and temazepam (15, 30, and 60 mg/70 kg) were administered orally in a randomized, double-blind, crossover design. Zolpidem, triazolam, and temazepam produced orderly dose-and time-related impairment of learning, recall, and performance, and increased subject-and observer-rated estimates of strength of drug effect. The absolute magnitude of these effects at peak effect were comparable across the three compounds. The time to maximal drug effect was faster with zolpidem (0.5-1.0 hours) than with triazolam (1.5-2.0 hours) or temazepam (2-3 hours). These results suggest that despite the somewhat unique benzodiazepine receptor-binding profile of zolpidem, its behavioral and subject-rated effects are similar to those of benzodiazepine hypnotics (ie, triazolam and temazepam).(J Clin Psychopharmacol 1996: 16: 146-157).